NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: HeartBeam's JP Morgan Healthcare Conference Attendance and FDA-Cleared Cardiac Technology
TL;DR
HeartBeam's FDA-cleared portable ECG technology offers investors early access to a disruptive cardiac care platform ahead of its 2026 commercial launch.
HeartBeam's cable-free system uses 3D ECG signals from five electrodes to synthesize 12-lead ECGs for arrhythmia assessment, with FDA clearance and over 20 patents.
This portable ECG technology enables cardiac monitoring outside medical facilities, improving early detection and access to care for patients with heart conditions.
HeartBeam's innovative cable-free device creates 12-lead ECGs from 3D signals, transforming how cardiac health is monitored beyond traditional clinical settings.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. announced it will attend the JP Morgan 2026 Annual Healthcare Conference where company executives will meet with investors and potential partners to discuss the company's FDA-cleared 12-lead ECG synthesis software ahead of a planned limited commercial launch in Q1 2026.
The conference is scheduled for January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco, with HeartBeam executives available for meetings from January 12–14.
Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available for off-site meetings with investors and potential commercialization and co-development partners.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, designed for portable use wherever the patient is located.
HeartBeam received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and clearance for its 12-Lead ECG synthesis software in December 2025.
The software is intended for manual assessment of normal sinus rhythm and non-life-threatening arrhythmias including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex.
The software is not intended for assessment of other arrhythmias or conditions including other atrial/ventricular arrhythmias, hypertrophy, conduction disorders, myocardial infarction or ischemia, pacemaker functions, localization of arrhythmia foci, or ECG wave abnormalities, and does not replace a standard 12-Lead ECG.
The portable technology allows physicians to identify cardiac health trends and acute conditions outside medical facilities, enabling patients to receive appropriate care guidance without needing to visit a healthcare facility.
HeartBeam plans a limited U.S. commercial launch in the first quarter of 2026, following the JP Morgan Healthcare Conference discussions.
For additional information, visit HeartBeam.com or view the full press release at https://nnw.fm/zvmUc.
Curated from InvestorBrandNetwork (IBN)
